查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1402892

胜肽治療市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2023-2031

Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 257 Pages | 商品交期: 2-10個工作天內

價格

胜肽治療市場 - 報告範圍

TMR 關於全球胜肽治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球胜肽治療市場的收入2017-2031年期間，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球胜肽治療市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解胜肽治療市場。

市場概況
2023年市場價值 378 億美元
2031 年市場價值 859 億美元
CAGR 9.6%

該報告深入探討了全球肽治療市場的競爭格局。全球肽治療市場的主要參與者已被確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球胜肽治療市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2023 - 2031 年全球市場分析與預測

第 5 章：關鍵見解

  • 2022 年獲得 FDA 批准
  • 2000年以來核准的胜肽類藥物及其標靶和適應症
  • 空白分析
  • 波特的分析
  • 管道分析
  • 多肽藥物化學結構趨勢分析
  • 用於胜肽類藥物的分離介質
  • COVID-19 影響分析

第 6 章：全球市場分析與預測：依產品類型

  • 簡介與定義
  • 主要發現/進展
  • 2023 - 2031 年按產品類型分類的市場價值預測
    • 創新的
    • 通用的
  • 按產品類型分類的市場吸引力

第 7 章：全球市場分析與預測：按應用分類

  • 簡介與定義
  • 主要發現/進展
  • 2023 - 2031 年按應用的市場價值預測
    • 新陳代謝
    • 腫瘤學
    • 胃腸道
    • 心血管
    • 神經病學
    • 其他
  • 按應用的市場吸引力

第 8 章：全球市場分析與預測：按管理途徑

  • 簡介與定義
  • 主要發現/進展
  • 2023 - 2031 年按給藥途徑分類的市場價值預測
    • 注射用
    • 口服
    • 其他
  • 按給藥途徑分類的市場吸引力

第 9 章：全球市場分析與預測：按胜肽類型

  • 簡介與定義
  • 主要發現/進展
  • 2023 - 2031 年胜肽類型市場價值預測
    • 天然胜肽
    • 類比胜肽
    • 異源胜肽
  • 按胜肽類型分類的市場吸引力

第 10 章：全球市場分析與預測：依技術分類

  • 簡介與定義
  • 主要發現/進展
  • 2023 - 2031 年技術市場價值預測
    • 液相
    • 固相
    • 混合
  • 技術的市場吸引力

第 11 章：全球市場分析與預測：依製造類型

  • 簡介與定義
  • 主要發現/進展
  • 2023 - 2031 年按製造類型分類的市場價值預測
    • 內部
    • 奇美歐
  • 按製造類型分類的市場吸引力

第 12 章：全球市場分析與預測：按地區

  • 主要發現
  • 各地區市場價值預測
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 按國家/地區分類的市場吸引力

第 13 章：北美市場分析與預測

第 14 章：歐洲市場分析與預測

第 15 章：亞太市場分析與預測

第 16 章：拉丁美洲市場分析與預測

第 17 章：中東和非洲市場分析與預測

第18章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 公司市佔率分析 (2022)
  • 公司簡介
    • Amgen, Inc.
    • Sachem Holding AG
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: TMRGL418

Peptide Therapeutics Market - Scope of Report

TMR's report on the global peptide therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global peptide therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics market.

Market Snapshot
Market Value in 2023US$ 37.8 Bn
Market Value in 2031US$ 85.9 Bn
CAGR9.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peptide therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide therapeutics market.

The report delves into the competitive landscape of the global peptide therapeutics market. Key players operating in the global peptide therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peptide therapeutics market profiled in this report.

Key Questions Answered in Global peptide therapeutics Market Report:

  • What is the sales/revenue generated by peptide therapeutics across all regions during the forecast period?
  • What are the opportunities in the global peptide therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Peptide Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global peptide therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peptide therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peptide therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Peptide Therapeutics Market

4. Market Overview

  • 4.1. Introduction
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Peptide Therapeutics Market Analysis and Forecasts, 2023 - 2031

5. Key Insights

  • 5.1. FDA-approved Peptide Therapeutics in 2022
  • 5.2. Peptide Drugs Approved Since 2000, with their Targets and Indications
  • 5.3. White Space Analysis
  • 5.4. Porter's Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Peptide Drugs Chemical Structure Trend Analysis
  • 5.7. Separation Media Used for Peptide Drugs
  • 5.8. COVID-19 Impact Analysis

6. Global Peptide Therapeutics Market Analysis and Forecasts, By Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Product Type, 2023 - 2031
    • 6.3.1. Innovative
    • 6.3.2. Generic
  • 6.4. Market Attractiveness By Product Type

7. Global Peptide Therapeutics Market Analysis and Forecasts, By Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Application, 2023 - 2031
    • 7.3.1. Metabolic
    • 7.3.2. Oncology
    • 7.3.3. Gastrointestinal
    • 7.3.4. Cardiovascular
    • 7.3.5. Neurological
    • 7.3.6. Others
  • 7.4. Market Attractiveness By Application

8. Global Peptide Therapeutics Market Analysis and Forecasts, By Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Route of Administration, 2023 - 2031
    • 8.3.1. Parenteral
    • 8.3.2. Oral
    • 8.3.3. Others
  • 8.4. Market Attractiveness By Route of Administration

9. Global Peptide Therapeutics Market Analysis and Forecasts, By Types of Peptide

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Types of Peptide, 2023 - 2031
    • 9.3.1. Native Peptides
    • 9.3.2. Analog Peptides
    • 9.3.3. Heterologous Peptides
  • 9.4. Market Attractiveness By Types of Peptide

10. Global Peptide Therapeutics Market Analysis and Forecasts, By Technology

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast By Technology, 2023 - 2031
    • 10.3.1. Liquid Phase
    • 10.3.2. Solid Phase
    • 10.3.3. Hybrid
  • 10.4. Market Attractiveness By Technology

11. Global Peptide Therapeutics Market Analysis and Forecasts, By Manufacturing Type

  • 11.1. Introduction & Definition
  • 11.2. Key Findings / Developments
  • 11.3. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 11.3.1. In-house
    • 11.3.2. CMO
  • 11.4. Market Attractiveness By Manufacturing Type

12. Global Peptide Therapeutics Market Analysis and Forecasts, By Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast By Region
    • 12.2.1. North America
    • 12.2.2. Europe
    • 12.2.3. Asia Pacific
    • 12.2.4. Latin America
    • 12.2.5. Middle East & Africa
  • 12.3. Market Attractiveness By Country/Region

13. North America Peptide Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Product Type,2023 - 2031
    • 13.2.1. Innovative
    • 13.2.2. Generic
  • 13.3. Market Value Forecast By Application,2023 - 2031
    • 13.3.1. Metabolic
    • 13.3.2. Oncology
    • 13.3.3. Gastrointestinal
    • 13.3.4. Cardiovascular
    • 13.3.5. Neurological
    • 13.3.6. Others
  • 13.4. Market Value Forecast By Route of Administration,2023 - 2031
    • 13.4.1. Parenteral
    • 13.4.2. Oral
    • 13.4.3. Others
  • 13.5. Market Value Forecast By Types of Peptide,2023 - 2031
    • 13.5.1. Native Peptides
    • 13.5.2. Analog Peptides
    • 13.5.3. Heterologous Peptides
  • 13.6. Market Value Forecast By Technology,2023 - 2031
    • 13.6.1. Liquid Phase
    • 13.6.2. Solid Phase
    • 13.6.3. Hybrid
  • 13.7. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 13.7.1. In-house
    • 13.7.2. CMO
  • 13.8. Market Value Forecast By Country,2023 - 2031
    • 13.8.1. U.S.
    • 13.8.2. Canada
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Product Type
    • 13.9.2. By Application
    • 13.9.3. By Route of Administration
    • 13.9.4. By Types of Peptide
    • 13.9.5. By Technology
    • 13.9.6. By Manufacturing Type
    • 13.9.7. By Country

14. Europe Peptide Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Product Type,2023 - 2031
    • 14.2.1. Innovative
    • 14.2.2. Generic
  • 14.3. Market Value Forecast By Application,2023 - 2031
    • 14.3.1. Metabolic
    • 14.3.2. Oncology
    • 14.3.3. Gastrointestinal
    • 14.3.4. Cardiovascular
    • 14.3.5. Neurological
    • 14.3.6. Others
  • 14.4. Market Value Forecast By Route of Administration,2023 - 2031
    • 14.4.1. Parenteral
    • 14.4.2. Oral
    • 14.4.3. Others
  • 14.5. Market Value Forecast By Types of Peptide,2023 - 2031
    • 14.5.1. Native Peptides
    • 14.5.2. Analog Peptides
    • 14.5.3. Heterologous Peptides
  • 14.6. Market Value Forecast By Technology,2023 - 2031
    • 14.6.1. Liquid Phase
    • 14.6.2. Solid Phase
    • 14.6.3. Hybrid
  • 14.7. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 14.7.1. In-house
    • 14.7.2. CMO
  • 14.8. Market Value Forecast By Country,2023 - 2031
    • 14.8.1. Germany
    • 14.8.2. U.K.
    • 14.8.3. France
    • 14.8.4. Spain
    • 14.8.5. Italy
    • 14.8.6. Rest of Europe
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Product Type
    • 14.9.2. By Application
    • 14.9.3. By Route of Administration
    • 14.9.4. By Types of Peptide
    • 14.9.5. By Technology
    • 14.9.6. By Manufacturing Type
    • 14.9.7. By Country

15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Product Type,2023 - 2031
    • 15.2.1. Innovative
    • 15.2.2. Generic
  • 15.3. Market Value Forecast By Application,2023 - 2031
    • 15.3.1. Metabolic
    • 15.3.2. Oncology
    • 15.3.3. Gastrointestinal
    • 15.3.4. Cardiovascular
    • 15.3.5. Neurological
    • 15.3.6. Others
  • 15.4. Market Value Forecast By Route of Administration,2023 - 2031
    • 15.4.1. Parenteral
    • 15.4.2. Oral
    • 15.4.3. Others
  • 15.5. Market Value Forecast By Types of Peptide,2023 - 2031
    • 15.5.1. Native Peptides
    • 15.5.2. Analog Peptides
    • 15.5.3. Heterologous Peptides
  • 15.6. Market Value Forecast By Technology,2023 - 2031
    • 15.6.1. Liquid Phase
    • 15.6.2. Solid Phase
    • 15.6.3. Hybrid
  • 15.7. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 15.7.1. In-house
    • 15.7.2. CMO
  • 15.8. Market Value Forecast By Country,2023 - 2031
    • 15.8.1. China
    • 15.8.2. Japan
    • 15.8.3. India
    • 15.8.4. Australia & New Zealand
    • 15.8.5. Rest of Asia Pacific
  • 15.9. Market Attractiveness Analysis
    • 15.9.1. By Product Type
    • 15.9.2. By Application
    • 15.9.3. By Route of Administration
    • 15.9.4. By Types of Peptide
    • 15.9.5. By Technology
    • 15.9.6. By Manufacturing Type
    • 15.9.7. By Country

16. Latin America Peptide Therapeutics Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast By Product Type,2023 - 2031
    • 16.2.1. Innovative
    • 16.2.2. Generic
  • 16.3. Market Value Forecast By Application,2023 - 2031
    • 16.3.1. Metabolic
    • 16.3.2. Oncology
    • 16.3.3. Gastrointestinal
    • 16.3.4. Cardiovascular
    • 16.3.5. Neurological
    • 16.3.6. Others
  • 16.4. Market Value Forecast By Route of Administration,2023 - 2031
    • 16.4.1. Parenteral
    • 16.4.2. Oral
    • 16.4.3. Others
  • 16.5. Market Value Forecast By Types of Peptide,2023 - 2031
    • 16.5.1. Native Peptides
    • 16.5.2. Analog Peptides
    • 16.5.3. Heterologous Peptides
  • 16.6. Market Value Forecast By Technology,2023 - 2031
    • 16.6.1. Liquid Phase
    • 16.6.2. Solid Phase
    • 16.6.3. Hybrid
  • 16.7. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 16.7.1. In-house
    • 16.7.2. CMO
  • 16.8. Market Value Forecast By Country,2023 - 2031
    • 16.8.1. Brazil
    • 16.8.2. Mexico
    • 16.8.3. Rest of Latin America
  • 16.9. Market Attractiveness Analysis
    • 16.9.1. By Product Type
    • 16.9.2. By Application
    • 16.9.3. By Route of Administration
    • 16.9.4. By Types of Peptide
    • 16.9.5. By Technology
    • 16.9.6. By Manufacturing Type
    • 16.9.7. By Country

17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast

  • 17.1. Introduction
    • 17.1.1. Key Findings
  • 17.2. Market Value Forecast By Product Type,2023 - 2031
    • 17.2.1. Innovative
    • 17.2.2. Generic
  • 17.3. Market Value Forecast By Application,2023 - 2031
    • 17.3.1. Metabolic
    • 17.3.2. Oncology
    • 17.3.3. Gastrointestinal
    • 17.3.4. Cardiovascular
    • 17.3.5. Neurological
    • 17.3.6. Others
  • 17.4. Market Value Forecast By Route of Administration,2023 - 2031
    • 17.4.1. Parenteral
    • 17.4.2. Oral
    • 17.4.3. Others
  • 17.5. Market Value Forecast By Types of Peptide,2023 - 2031
    • 17.5.1. Native Peptides
    • 17.5.2. Analog Peptides
    • 17.5.3. Heterologous Peptides
  • 17.6. Market Value Forecast By Technology,2023 - 2031
    • 17.6.1. Liquid Phase
    • 17.6.2. Solid Phase
    • 17.6.3. Hybrid
  • 17.7. Market Value Forecast By Manufacturing Type,2023 - 2031
    • 17.7.1. In-house
    • 17.7.2. CMO
  • 17.8. Market Value Forecast By Country,2023 - 2031
    • 17.8.1. GCC Countries
    • 17.8.2. South Africa
    • 17.8.3. Rest of Middle East & Africa
  • 17.9. Market Attractiveness Analysis
    • 17.9.1. By Product Type
    • 17.9.2. By Application
    • 17.9.3. By Route of Administration
    • 17.9.4. By Types of Peptide
    • 17.9.5. By Technology
    • 17.9.6. By Manufacturing Type
    • 17.9.7. By Country

18. Competition Landscape

  • 18.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 18.2. Market Share Analysis By Company (2022)
  • 18.3. Company Profiles
    • 18.3.1. Amgen, Inc.
      • 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. Financial Overview
      • 18.3.1.4. SWOT Analysis
      • 18.3.1.5. Strategic Overview
    • 18.3.2. Sachem Holding AG
      • 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. Financial Overview
      • 18.3.2.4. SWOT Analysis
      • 18.3.2.5. Strategic Overview
    • 18.3.3. Eli Lilly and Company
      • 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. Financial Overview
      • 18.3.3.4. SWOT Analysis
      • 18.3.3.5. Strategic Overview
    • 18.3.4. F. Hoffmann-La Roche Ltd.
      • 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. Financial Overview
      • 18.3.4.4. SWOT Analysis
      • 18.3.4.5. Strategic Overview
    • 18.3.5. GlaxoSmithKline plc
      • 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. Financial Overview
      • 18.3.5.4. SWOT Analysis
      • 18.3.5.5. Strategic Overview
    • 18.3.6. Novartis AG
      • 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. Financial Overview
      • 18.3.6.4. SWOT Analysis
      • 18.3.6.5. Strategic Overview
    • 18.3.7. Pfizer, Inc.
      • 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. Financial Overview
      • 18.3.7.4. SWOT Analysis
      • 18.3.7.5. Strategic Overview
    • 18.3.8. Sanofi
      • 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. Financial Overview
      • 18.3.8.4. SWOT Analysis
      • 18.3.8.5. Strategic Overview
    • 18.3.9. Takeda Pharmaceutical Company Limited
      • 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. Financial Overview
      • 18.3.9.4. SWOT Analysis
      • 18.3.9.5. Strategic Overview
    • 18.3.10. Teva Pharmaceutical Industries Ltd.
      • 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. Financial Overview
      • 18.3.10.4. SWOT Analysis
      • 18.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 02: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 03: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 04: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
  • Table 05: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 06: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, Manufacturing Type, 2023-2031
  • Table 07: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Region, 2023-2031
  • Table 08: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 09: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 10: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 11: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 12: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
  • Table 13: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 14: North America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
  • Table 15: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 16: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 17: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 18: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 19: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
  • Table 20: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 21: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
  • Table 22: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 23: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 24: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 25: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 26: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Types of Peptide, 2023-2031
  • Table 27: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 28: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
  • Table 29: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 30: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 31: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 32: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 33: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Type of Peptide, 2023-2031
  • Table 34: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 35: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
  • Table 36: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 37: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2023-2031
  • Table 38: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2031
  • Table 39: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 40: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Type of Peptide, 2023-2031
  • Table 41: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Technology, 2023-2031
  • Table 42: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast, by Manufacturing Type, 2023-2031
  • Table 43: Global Peptide Therapeutics Market: Company Share Analysis, 2022

List of Figures

  • Figure 01: Global Peptide Therapeutics Market Size, by Application, 2022
  • Figure 02: Peptide Therapeutics Market share (%), by Application, 2022
  • Figure 03: Peptide Therapeutics Market Size, by Route of Administration, 2022
  • Figure 04: Peptide Therapeutics Market share (%), by Route of Administration, 2022
  • Figure 05: Peptide Therapeutics Market Size, by Product Type, 2022
  • Figure 06: Peptide Therapeutics Market share (%), by Product Type, 2022
  • Figure 07: Peptide Therapeutics Market Size, by Types of Peptide, 2022
  • Figure 08: Peptide Therapeutics Market share (%), by Types of Peptide, 2022
  • Figure 09: Peptide Therapeutics Market Size, by Technology, 2022
  • Figure 10: Peptide Therapeutics Market share (%), by Technology, 2022
  • Figure 11: Peptide Therapeutics Market Size, by Manufacturing Type, 2022
  • Figure 12: Peptide Therapeutics Market share (%), by Manufacturing Type, 2022
  • Figure 13: Global Peptide Therapeutics Market, By Region (2022 and 2031)
  • Figure 14: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 16: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022
  • Figure 15: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 17: Global Peptide Therapeutics Market Value Share Analysis, by Product Type, 2031
  • Figure 18: Global Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 19: Global Peptide Therapeutics Market Value (US$ Mn), by Innovative, 2023-2031
  • Figure 20: Global Peptide Therapeutics Market Value Share Analysis, by Innovative, 2022 and 2031
  • Figure 21: Global Peptide Therapeutics Market Value (US$ Mn), by Generic, 2023-2031
  • Figure 22: Global Peptide Therapeutics Market Value Share Analysis, by Generic, 2022 and 2031
  • Figure 23: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 24: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2022
  • Figure 25: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2031
  • Figure 26: Global Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 27: Global Peptide Therapeutics Market Value (US$ Mn), by Metabolic, 2023-2031
  • Figure 28: Global Peptide Therapeutics Market Value Share Analysis, by Metabolic, 2022 and 2031
  • Figure 29: Global Peptide Therapeutics Market Value (US$ Mn), by Oncology, 2023-2031
  • Figure 30: Global Peptide Therapeutics Market Value Share Analysis, by Oncology, 2022 and 2031
  • Figure 31: Global Peptide Therapeutics Market Value (US$ Mn), by Gastrointestinal, 2023-2031
  • Figure 32: Global Peptide Therapeutics Market Value Share Analysis, by Gastrointestinal, 2022 and 2031
  • Figure 33: Global Peptide Therapeutics Market Value (US$ Mn), by Cardiovascular, 2023-2031
  • Figure 34: Global Peptide Therapeutics Market Value Share Analysis, by Cardiovascular, 2022 and 2031
  • Figure 35: Global Peptide Therapeutics Market Value (US$ Mn), by Neurological, 2023-2031
  • Figure 36: Global Peptide Therapeutics Market Value Share Analysis, by Neurological, 2022 and 2031
  • Figure 37: Global Peptide Therapeutics Market Value (US$ Mn), by Others, 2023-2031
  • Figure 38: Global Peptide Therapeutics Market Value Share Analysis, by Others, 2022 and 2031
  • Figure 39: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2022 and 2031
  • Figure 40: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2022
  • Figure 41: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration Type, 2031
  • Figure 42: Global Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration Type, 2023-2031
  • Figure 43: Global Peptide Therapeutics Market Value (US$ Mn), by Parenteral, 2023-2031
  • Figure 44: Global Peptide Therapeutics Market Value Share Analysis, by Parenteral, 2022 and 2031
  • Figure 45: Global Peptide Therapeutics Market Value (US$ Mn), by Oral, 2023-2031
  • Figure 46: Global Peptide Therapeutics Market Value Share Analysis, by Oral, 2022 and 2031
  • Figure 47: Global Peptide Therapeutics Market Value (US$ Mn), by Others, 2023-2031
  • Figure 48: Global Peptide Therapeutics Market Value Share Analysis, by Others, 2022 and 2031
  • Figure 49: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2022 and 2031
  • Figure 50: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2022
  • Figure 51: Global Peptide Therapeutics Market Value Share Analysis, by Types of Peptide Type, 2031
  • Figure 52: Global Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide Type, 2023-2031
  • Figure 53: Global Peptide Therapeutics Market Value (US$ Mn), by Native Peptides, 2023-2031
  • Figure 54: Global Peptide Therapeutics Market Value Share Analysis, by Native Peptides, 2022 and 2031
  • Figure 55: Global Peptide Therapeutics Market Value (US$ Mn), by Analog Peptides, 2023-2031
  • Figure 56: Global Peptide Therapeutics Market Value Share Analysis, by Analog Peptides, 2022 and 2031
  • Figure 57: Global Peptide Therapeutics Market Value (US$ Mn), by Heterologous Peptides, 2023-2031
  • Figure 58: Global Peptide Therapeutics Market Value Share Analysis, by Heterologous Peptides, 2022 and 2031
  • Figure 59: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2022 and 2031
  • Figure 60: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2022
  • Figure 61: Global Peptide Therapeutics Market Value Share Analysis, by Technology Type, 2031
  • Figure 62: Global Peptide Therapeutics Market Attractiveness Analysis, by Technology Type, 2023-2031
  • Figure 63: Global Peptide Therapeutics Market Value (US$ Mn), by Liquid Phase, 2023-2031
  • Figure 64: Global Peptide Therapeutics Market Value Share Analysis, by Liquid Phase, 2022 and 2031
  • Figure 65: Global Peptide Therapeutics Market Value (US$ Mn), by Solid Phase, 2023-2031
  • Figure 66: Global Peptide Therapeutics Market Value Share Analysis, by Solid Phase, 2022 and 2031
  • Figure 67: Global Peptide Therapeutics Market Value (US$ Mn), by Hybrid, 2023-2031
  • Figure 68: Global Peptide Therapeutics Market Value Share Analysis, by Hybrid, 2022 and 2031
  • Figure 69: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type , 2022 and 2031
  • Figure 70: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type , 2022
  • Figure 71: Global Peptide Therapeutics Market Value Share Analysis, Manufacturing Type , 2031
  • Figure 72: Global Peptide Therapeutics Market Attractiveness Analysis, Manufacturing Type , 2023-2031
  • Figure 73: Global Peptide Therapeutics Market Value (US$ Mn), by In-house, 2023-2031
  • Figure 74: Global Peptide Therapeutics Market Value Share Analysis, by In-house, 2022 and 2031
  • Figure 75: Global Peptide Therapeutics Market Value (US$ Mn), by CMO, 2023-2031
  • Figure 76: Global Peptide Therapeutics Market Value Share Analysis, by CMO, 2022 and 2031
  • Figure 77: Global Peptide Therapeutics Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 78: Global Peptide Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 79: North America Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
  • Figure 80: North America Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 81: North America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 82: North America Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 83: North America Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 84: North America Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 85: North America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 86: North America Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 87: North America Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 88: North America Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031
  • Figure 89: North America Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031
  • Figure 90: North America Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 91: North America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 92: North America Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
  • Figure 93: North America Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
  • Figure 94: Europe Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
  • Figure 95: Europe Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 96: Europe Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 97: Europe Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 98: Europe Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 99: Europe Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 100: Europe Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 101: Europe Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 102: Europe Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 103: Europe Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031
  • Figure 104: Europe Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031
  • Figure 105: Europe Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 106: Europe Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 107: Europe Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
  • Figure 108: Europe Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
  • Figure 109: Asia Pacific Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
  • Figure 110: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 111: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 112: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 113: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 114: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 115: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 116: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 117: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 118: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Types of Peptide, 2022 and 2031
  • Figure 119: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Types of Peptide, 2023-2031
  • Figure 120: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 121: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 122: Asia Pacific Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
  • Figure 123: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
  • Figure 124: Latin America Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
  • Figure 125: Latin America Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 126: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 127: Latin America Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 128: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 129: Latin America Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 130: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 131: Latin America Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 132: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 133: Latin America Peptide Therapeutics Market Value Share Analysis, by Type of Peptide, 2022 and 2031
  • Figure 134: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Type of Peptide, 2023-2031
  • Figure 135: Latin America Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 136: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 137: Latin America Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
  • Figure 138: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
  • Figure 139: Middle East & Africa Peptide Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023-2031
  • Figure 140: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 141: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 142: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 143: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 144: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 145: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 146: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 147: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 148: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Type of Peptide, 2022 and 2031
  • Figure 149: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Type of Peptide, 2023-2031
  • Figure 150: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 151: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 152: Middle East & Africa Peptide Therapeutics Market Value Share Analysis, by Manufacturing Type, 2022 and 2031
  • Figure 153: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Manufacturing Type, 2023-2031
  • Figure 154: Global Peptide Therapeutics Market: Company Share Analysis, 2022